drugset / Trial / NCT05906576
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
NaSingle-groupOpen-labelTreatment
Summary
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
Timeline
- Start
- 2023-09-21
- Primary completion
- 2026-11
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | — | — |